Brum, Wagner S. http://orcid.org/0000-0002-9777-0559
Cullen, Nicholas C.
Janelidze, Shorena
Ashton, Nicholas J.
Zimmer, Eduardo R. http://orcid.org/0000-0002-5349-0053
Therriault, Joseph http://orcid.org/0000-0002-7826-4781
Benedet, Andrea L.
Rahmouni, Nesrine
Tissot, Cécile http://orcid.org/0000-0003-2711-3833
Stevenson, Jenna
Servaes, Stijn
Triana-Baltzer, Gallen
Kolb, Hartmuth C. http://orcid.org/0000-0003-2414-5792
Palmqvist, Sebastian http://orcid.org/0000-0002-9267-1930
Stomrud, Erik
Rosa-Neto, Pedro http://orcid.org/0000-0001-9116-1376
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Hansson, Oskar http://orcid.org/0000-0001-8467-7286
Article History
Received: 11 January 2023
Accepted: 18 July 2023
First Online: 31 August 2023
Competing interests
: O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Genentech, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. K.B. has served as a consultant, at advisory boards, or at data monitoring committees, for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. G.T.-B. and H.C.K. are employees of Janssen Research and Development. The remaining authors declare no competing interests.